Aktis Oncology Announces Completion of $84M Series A+ Financing
ADC评论
August 30, 2022
Aktis Oncology, a biotechnology company focused on the discovery and development of novel targeted alpha radiopharmaceuticals to treat solid tumors, announced the completion of an
